Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
Completed · Phase 3
Conditions studied: Melanoma, Skin Cancer
In brief
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa plus combination chemotherapy and interleukin-2 is more effective than interferon alfa alone in treating patients with melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy plus interleukin-2 in treating patients with melanoma.
Key facts
- Study ID
- NCT00002882
- Run by
- M.D. Anderson Cancer Center
- People needed
- 140
- Starts
- 1995-11-01
- Expected to finish
- 2006-04-01
- Last updated by the study team
- 2011-12-13
Who can join
Age: 10 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.